Study on the Effects of Left Ventricular Assist Device Implantation on the Phenotype of Blood Platelets and Leucocytes
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Cardiac Insufficiency
- Sponsor
- University Hospital, Toulouse
- Enrollment
- 4
- Locations
- 1
- Primary Endpoint
- Platelet activation
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
To compare in vivo platelet and leukocyte activation and phenotype before and after Left ventricular assist device (LAVD) implantation
Detailed Description
The present study plan to investigate platelet activation in vivo using a variety of biomarkers previously identified as sensitive to high shear stress in patients with severe aortic valve stenosis before and after trans arterial valve replacement. As one of the best biomarker is a high degree of platelet-leukocyte interactions, the study will study in parallel leukocytes activation/differentiation. These parameters will be compared at 3 time-points, before and after LAVD implantation in ambulatory patients.
Investigators
Eligibility Criteria
Inclusion Criteria
- •elective implantation of LAVD (Heartmate II),
- •written informed consent to the study
- •Patients with health insurance
Exclusion Criteria
- •treatment or procedure that could affect platelet functions or turn-over(low-dose aspirin is allowed).
- •Pregnancy or breastfeeding
- •Juridical Protection
Outcomes
Primary Outcomes
Platelet activation
Time Frame: Month 2 after LAVD implantation
To compare platelet activation in vivo, using a composite criteria determinated by variety of biomarkers of activation analysed by flow cytometry and enzyme-linked immunosorbent assay (ELISA)
Secondary Outcomes
- Changes in leukocyte phenotype(Month 2 after LAVD implantation)
- Level of circulating platelet-leukocyte conjugate(Month 2 after LAVD implantation)